Drug
Elismetrep clinical trials
Also written MT-8554.
- studies test it
- 14
- open now
- 3
- in phase 3
- 3
- first study started
- 2015
Keep track of what changes. Save the elismetrep studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Tanabe Pharma Corporation (6) · Kallyope Inc. (4) · Tanabe Pharma America, Inc. (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses elismetrep is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigraineRecruitingPhase 3Kallyope Inc.NCT07674654Written as Elismetrep
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineRecruitingPhase 3Kallyope Inc.NCT07816367Written as Elismetrep
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineRecruitingPhase 3Kallyope Inc.NCT07645924Written as Elismetrep
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of MigraineCompletedPhase 2Kallyope Inc.NCT06848075Written as Elismetrep (K-304) 2 mg
- MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenCompletedPhase 2Tanabe Pharma America, Inc.NCT03291067Written as MT-8554 1mg
- Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor SymptomsCompletedPhase 2Tanabe Pharma America, Inc.NCT03541200Written as MT-8554
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor SymptomsCompletedPhase 1Tanabe Pharma CorporationNCT02803268Written as MT-8554 low dose
- Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral NeuropathyCompletedPhase 2Tanabe Pharma CorporationNCT05123196Written as MT-8554
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT02429102Written as MT-8554
- A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT02536209Written as MT-8554 low dose
- A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT02675309Written as MT-8554
- Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral NeuropathyCompletedPhase 2Tanabe Pharma CorporationNCT03172598Written as MT-8554 low dose
- Definitive QT Study With MT-8554CompletedPhase 1Tanabe Pharma America, Inc.NCT03471130Written as MT-8554 Low dose
- Mass Balance Study With MT-8554CompletedPhase 1Tanabe Pharma America, Inc.NCT03381404Written as [14C] MT-8554
Codes
What other systems call elismetrep · ClinicalTrials.gg INT017070
- UNII (FDA) KIB8V5UR7DELISMETREPOne source FDA
- NCI Thesaurus C169937ElismetrepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KIB8V5UR7D | ELISMETREP | One source FDA |
| NCI Thesaurus | C169937 | Elismetrep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.